Literature DB >> 34187430

Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study.

Zhenhua Lu1,2, Zhen Sun1,3, Chengyu Liu1,2, Xiaolei Shi1, Rui Li1,3, Weiwei Shao1, Yangyang Zheng1, Yao Li1, Jinghai Song4,5.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is an effective treatment option for hepatocellular carcinoma (HCC). This study aimed to analyze the prognostic factors of HCC patients treated with RFA and to develop nomograms for outcome prediction.
METHODS: A total of 3142 HCC patients treated with RFA were recruited, and their data were collected from the Surveillance, Epidemiology, and End Results database. Univariate and multifactor Cox analyses were performed to identify independent prognostic factors. These factors were integrated into a nomogram to predict 3- and 5-year cancer-specific survival (CSS) and overall survival (OS). Consistency indices and calibration plots were used to assess the accuracy of the nomograms in both the internal and external cohorts.
RESULTS: The median follow-up periods for HCC patients treated with RFA were 27 and 29 months for OS and CSS, respectively. Marital status, age, race, histological grade of differentiation, tumor size, T stage, and serum alpha-fetoprotein levels at the time of diagnosis were identified as prognostic factors for OS and CSS. Additionally, M stage was identified as risk factors for OS. These risk factors are included in the nomogram. The calibration plots of the OS and CSS nomograms showed excellent consistency between actual survival and nomogram predictions. The bootstrap-corrected concordance indices of the OS and CSS nomograms were 0.637 (95% CI, 0.628-0.646) and 0.670 (95% 0.661-0.679), respectively. Importantly, our nomogram performed better discriminatory compared with 8th edition tumor-node-metastasis (TNM) stage system for predicting OS and CSS.
CONCLUSIONS: We identified prognostic factors for HCC patients treated with RFA and provided an accurate and personalized survival prediction scheme.

Entities:  

Keywords:  Cancer-specific survival (CSS); Hepatocellular carcinoma; Nomogram; Overall survival (OS); Radiofrequency ablation

Year:  2021        PMID: 34187430     DOI: 10.1186/s12885-021-08505-0

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  21 in total

1.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

Review 2.  How to build and interpret a nomogram for cancer prognosis.

Authors:  Alexia Iasonos; Deborah Schrag; Ganesh V Raj; Katherine S Panageas
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

3.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Authors:  Tito Livraghi; Franca Meloni; Michele Di Stasi; Emanuela Rolle; Luigi Solbiati; Carmine Tinelli; Sandro Rossi
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

4.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

5.  A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.

Authors:  Seo Hee Choi; Seung Woo Park; Jinsil Seong
Journal:  Radiother Oncol       Date:  2018-08-31       Impact factor: 6.280

6.  Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.

Authors:  Yi-Peng Fu; Yong Yi; Jin-Long Huang; Chu-Yu Jing; Jian Sun; Xiao-Chun Ni; Zhu-Feng Lu; Ya Cao; Jian Zhou; Jia Fan; Shuang-Jian Qiu
Journal:  Oncologist       Date:  2017-04-24

7.  Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma.

Authors:  Samer Tohme; David A Geller; Jon S Cardinal; Hui-Wei Chen; Vignesh Packiam; Srinevas Reddy; Jennifer Steel; James W Marsh; Allan Tsung
Journal:  HPB (Oxford)       Date:  2012-08-12       Impact factor: 3.647

8.  The changing epidemiology of primary liver cancer.

Authors:  Jessica L Petrick; Katherine A McGlynn
Journal:  Curr Epidemiol Rep       Date:  2019-05-03

Review 9.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

10.  Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry.

Authors:  Seung Ho Lee; Young-Joo Jin; Jin-Woo Lee
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

View more
  1 in total

1.  Development and Validation of a Nomogram to Predict Cancer-Specific Survival for Middle-Aged Patients With Early-Stage Hepatocellular Carcinoma.

Authors:  Chong Wen; Jie Tang; Hao Luo
Journal:  Front Public Health       Date:  2022-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.